Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients.

[1]  J. Uribarri,et al.  Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. , 2003, Journal of the American Society of Nephrology : JASN.

[2]  M. Peppa,et al.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Peter Stenvinkel,et al.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.

[4]  E. Fisher,et al.  Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. , 2002, Atherosclerosis.

[5]  C. Wanner,et al.  Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.

[6]  M. Peppa,et al.  Oxidative Stress-Inducing Carbonyl Compounds From Common Foods: Novel Mediators of Cellular Dysfunction , 2002, Molecular medicine.

[7]  M. Steffes,et al.  Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products , 2002, Diabetes/metabolism research and reviews.

[8]  H. Vlassara,et al.  Diabetes and advanced glycation endproducts , 2002, Journal of internal medicine.

[9]  T. Henle.  A Food Chemist'S View of Advanced Glycation End-Products , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[10]  L. Cooper,et al.  USRDS. 2001 Annual Data Report. , 2001, Nephrology news & issues.

[11]  P. Kris-Etherton,et al.  Validation for MEDFICTS, a dietary assessment instrument for evaluating adherence to total and saturated fat recommendations of the National Cholesterol Education Program Step 1 and Step 2 diets. , 2001, Journal of the American Dietetic Association.

[12]  M. F. Weiss,et al.  Mechanisms for the formation of glycoxidation products in end-stage renal disease. , 2000, Kidney international.

[13]  A. Levey,et al.  Cardiovascular disease and chronic renal disease: a new paradigm. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  B. Nilsson.  Biological effects of aminoguanidine: An update , 1999, Inflammation Research.

[15]  H. Vlassara,et al.  Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. , 1999, Diabetes.

[16]  H. Vlassara,et al.  Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. , 1997, Journal of immunological methods.

[17]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Baynes,et al.  Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging , 1996, Drugs & aging.

[19]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[20]  L. Raij,et al.  Cardiovascular risk factors in chronic renal failure and hemodialysis populations. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  P. Morrissey,et al.  Nutritional and toxicological aspects of the Maillard browning reaction in foods. , 1989, Critical reviews in food science and nutrition.

[22]  Y. Saint-Jalm,et al.  Determination of α-dicarbonyl compounds in cigarette smoke , 1981 .